Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.

Andrew G. Hinson net worth and biography

Andrew Hinson Biography and Net Worth

Director of BioLife Solutions

Andrew Hinson joined the Board in February 2007. Mr. Hinson served as Vice President of Clinical and Regulatory Affairs for LoneStar Heart, Inc. from 2004 to 2016. Mr. Hinson previously served as the Senior Director of research and clinical development at AnGes MG, Inc. (TSE: 4563) a biotechnology firm engaged in the development and commercialization of novel gene and cell therapies for the treatment of cardiovascular disease. Prior to that Mr. Hinson had a long career with Procter & Gamble Pharmaceutical (NYSE:PG) holding multiple technical and management positions in research, clinical development and medical affairs. Mr. Hinson has diverse experience in the cell and gene therapy markets and extensive experience with regulatory affairs and clinical development of new therapies for cardiac, neurologic, and gastrointestinal diseases. The Board has determined that Mr. Hinson should serve as a director because of his experience and knowledge of companies in the biotechnology space.

What is Andrew G. Hinson's net worth?: The estimated net worth of Andrew G. Hinson is at least $484,118.25 as of June 15th, 2021. Mr. Hinson owns 17,675 shares of BioLife Solutions stock worth more than $484,118 as of December 21st. This net worth approximation does not reflect any other investments that Mr. Hinson may own. Learn More about Andrew G. Hinson's net worth.
How do I contact Andrew G. Hinson?: The corporate mailing address for Mr. Hinson and other BioLife Solutions executives is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. BioLife Solutions can also be reached via phone at (425) 402-1400 and via email at [email protected]. Learn More on Andrew G. Hinson's contact information.
Has Andrew G. Hinson been buying or selling shares of BioLife Solutions?: Andrew G. Hinson has not been actively trading shares of BioLife Solutions during the past quarter. Most recently, Andrew G. Hinson sold 2,500 shares of the business's stock in a transaction on Monday, August 16th. The shares were sold at an average price of $44.51, for a transaction totalling $111,275.00. Following the completion of the sale, the director now directly owns 17,675 shares of the company's stock, valued at $786,714.25. Learn More on Andrew G. Hinson's trading history.
Who are BioLife Solutions' active insiders?: BioLife Solutions' insider roster includes Sarah Aebersold (VP), Todd Berard (CMO), Roderick de Greef (CFO), Karen Foster (Insider), Andrew Hinson (Director), Aby Mathew (VP), Michael Rice (CEO), Joseph Schick (Director), Marcus Schulz (CRO), and Troy Wichterman (CFO). Learn More on BioLife Solutions' active insiders.
Are insiders buying or selling shares of BioLife Solutions?: In the last twelve months, insiders at the medical equipment provider sold shares 75 times. They sold a total of 143,570 shares worth more than $2,926,356.42. The most recent insider tranaction occured on December, 16th when EVP Aby J Mathew sold 7,604 shares worth more than $207,817.32. Insiders at BioLife Solutions own 2.2% of the company. Learn More about insider trades at BioLife Solutions.
Information on this page was last updated on 12/16/2024.

Andrew G. Hinson Insider Trading History at BioLife Solutions

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/16/2021	Sell	2,500	$44.51	$111,275.00	17,675
7/15/2021	Sell	2,500	$44.44	$111,100.00
6/15/2021	Sell	2,500	$38.35	$95,875.00	17,675
5/17/2021	Sell	2,500	$29.06	$72,650.00	9,461
4/15/2021	Sell	2,500	$33.80	$84,500.00	12,473
3/15/2021	Sell	2,500	$37.32	$93,300.00	15,761
2/16/2021	Sell	2,500	$45.67	$114,175.00	16,961
10/30/2019	Sell	6,000	$17.87	$107,220.00	20,461
9/30/2019	Sell	6,000	$16.01	$96,060.00	9,747
8/30/2019	Sell	6,000	$20.07	$120,420.00	15,747
7/30/2019	Sell	6,000	$18.82	$112,920.00	21,747
7/1/2019	Sell	6,000	$17.33	$103,980.00	27,747
5/30/2019	Sell	6,000	$17.50	$105,000.00	33,747
4/30/2019	Sell	6,000	$17.19	$103,140.00
12/13/2018	Sell	4,000	$12.05	$48,200.00	45,747
6/13/2018	Sell	10,000	$11.25	$112,500.00

Andrew G. Hinson Buying and Selling Activity at BioLife Solutions

BioLife Solutions Company Overview

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

Today's Range

Now: $27.39

$25.13

$28.63

50 Day Range

MA: $24.96

$20.47

$27.47

2 Week Range

Now: $27.39

$14.50

$28.88

Volume

1,077,464 shs

Average Volume

386,862 shs

Market Capitalization

$1.27 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.91

AI breakthrough about to upend industry

From Porter & Company | Ad

I urge you to watch it now.